Table 4.

Associations between subject characteristics and patient-reported outcomes and a) development of AIMSS and b) early treatment discontinuation due to musculoskeletal symptoms.

	Development of AIMSS		Early Treatment Discontinuation
Baseline Characteristic	Odds ratio (95% CI)	P value	Odds ratio (95% CI)	P value
Age (<55 vs ≥55)	0.18 (0.01–3.1)	0.24	0.23 (0.01–4.2)	0.32
BMI (<25, 25–30, >30)	0.43 (0.11–1.7)	0.22	0.16 (0.03–0.84)	0.03
Prior tamoxifen (no, yes)	0.21 (0.02–3.1)	0.26	0.05 (0.002–1.0)	0.05
Prior chemotherapy (no, yes)	0.26 (0.04–1.9)	0.19	0.19 (0.02–1.74)	0.14
HAQ score	0.59 (0.31–1.1)	0.11	0.73 (0.38–1.43)	0.36
VAS score	1.26 (0.77–2.1)	0.36	0.90 (0.52–1.55)	0.70
DASH score	1.04 (0.92–1.2)	0.52	1.09 (0.96–1.25)	0.17
Change in Measurement (baseline and 3 mo)
HAQ	1.15 (0.57–2.3)	0.70	1.39 (0.68–2.88)	0.37
VAS	1.56 (0.42–5.8)	0.51	1.43 (0.46–4.48)	0.54
DASH	1.05 (0.91–1.2)	0.52	1.09 (0.93–1.29)	0.28
Change in Measurement (baseline and 12 mo)
HAQ	2.76 (0.3–26.6)	0.38	6.02 (0.4–83.8)	0.18
VAS	2.11 (1.1–4.2)	0.03	2.12 (1.1–4.1)	0.02